Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer’s disease, and features dormant and discontinued products.

These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.

Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.

Scope

– Which companies are the most active within the pipeline for cognitive impairment disorders?

– Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies mentioned

AB Science SA

AbbVie Inc

AC Immune SA

Acadia Pharmaceuticals Inc

Accera Inc

Acorda Therapeutics Inc

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

AFFiRiS AG

AgeneBio Inc

Alector LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Allinky Biopharma

ALSP Inc

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings Inc

Amgen Inc

Anavex Life Sciences Corp

Annexon Inc

Aphios Corp

Apodemus AB

Applied Research using OMIC Sciences SL

Aptevo Therapeutics Inc

Araclon Biotech SL

Archer Pharmaceuticals Inc

ArmaGen Inc

Asceneuron SA

Astellas Pharma Inc

AstraZeneca Plc

Aucta Pharmaceuticals LLC

Avineuro Pharmaceuticals Inc

Avraham Pharmaceuticals Ltd

Axon Neuroscience SE

Axovant Sciences Ltd

Axsome Therapeutics Inc

Axxam SpA

AZTherapies Inc

Beactica AB

Berg LLC

BioArctic AB

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Bsim2

Cadent Therapeutics

Cantabio Pharmaceuticals Inc

Cardax Inc

Carna Biosciences Inc

Celon Pharma SA

CereSpir Inc

CHA Bio & Diostech Co Ltd

Clera Inc

Cognition Therapeutics Inc

Cognosci Inc

CohBar Inc

Connexios Life Sciences Pvt Ltd

ConSynance Therapeutics Inc

Corium International Inc

Coronis NeuroSciences Ltd

Cortice Biosciences Inc

Cotinga Pharmaceuticals Inc

Crossbeta Biosciences BV

Cypralis Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Daval International Ltd

Denali Therapeutics Inc

Diffusion Pharmaceuticals Inc

Dongkook Pharmaceutical Co Ltd

Dr. August Wolff GmbH & Co KG Arzneimittel

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Ensemble Therapeutics Corp

Epigen Biosciences Inc

Evotec AG

F. Hoffmann-La Roche Ltd

Genentech Inc

Genervon Biopharmaceuticals LLC

Genzyme Corp

GlaxoSmithKline Plc

GliaCure Inc

Glialogix Inc

Golden Biotechnology Corp

Grifols SA

H. Lundbeck AS

Hemostemix Inc

Heptares Therapeutics Ltd

HitGen LTD

Hyundai Pharmaceutical Co Ltd

ICB International Inc

Ichor Medical Systems Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Immungenetics AG

Immunwork Inc

Impel NeuroPharma Inc

India Globalization Capital Inc

Insys Therapeutics Inc

IntelGenx Corp

Intellect Neurosciences Inc

Intra-Cellular Therapies Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Iproteos SL

IRLAB Therapeutics AB

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Kadmon Corp LLC

Karuna Pharmaceuticals Inc

Krenitsky Pharmaceuticals Inc

K-Stemcell Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Ltd

Lupin Ltd

M3 Biotechnology Inc

ManRos Therapeutics

MedDay SA

Medesis Pharma SA

MedImmune LLC

MediPost Co Ltd

MEDRx Co Ltd

MEI Pharma Inc

Merck & Co Inc

Microlin Bio Inc

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

ModGene Pharma LLC

Montisera Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NeoNeuro SAS

Neuraltus Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

Neurimmune Holding AG

Neuro Bio Ltd

NeuroGenetic Pharmaceuticals Inc

Neuron Biopharma SA

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

Neuro-Sys SAS

Neurotez Inc

New World Laboratories Inc

NoNO Inc

Novartis AG

Nymox Pharmaceutical Corp

Octapharma AG

Oryzon Genomics SA

Otsuka Holdings Co Ltd

Ovensa Inc

Oxstem Ltd

P2D Bioscience

Pacific Northwest Biotechnology LLC

Pain Therapeutics Inc

Peptron Inc

Pfizer Inc

Pharmasum Therapeutics AS

Pharmaxis Ltd

Pharnext SA

Phoenix Biotechnology Inc

Prana Biotechnology Ltd

Prevacus Inc

Priavoid GmbH

Probiodrug AG

Progenra Inc

ProMIS Neurosciences Inc

ProQR Therapeutics NV

Proteome Sciences Plc

Proteostasis Therapeutics Inc

Sage Therapeutics Inc

Saniona AB

SBI Pharmaceuticals Co Ltd

Sinil Pharmaceutical Co Ltd

Spherium Biomed SL

Stemedica Cell Technologies Inc

Sumitomo Dainippon Pharma Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Co Ltd

TauRx Therapeutics Ltd

Theranexus SAS

Therapix Biosciences Ltd

Vanda Pharmaceuticals Inc

Vicore Pharma AB

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

WhanIn Pharmaceutical Co Ltd

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 10

2 Introduction 12

2.1 Cognitive Impairment Disorders Report Coverage 12

2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 12

2.3 Dementia - Overview 12

2.4 Mild Cognitive Impairment - Overview 12

2.5 Alzheimer's Disease - Overview 12

3 Therapeutics Development 13

3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 13

3.2 Dementia 18

3.3 Mild Cognitive Impairment 30

3.4 Alzheimer's Disease 36

4 Therapeutics Assessment 90

4.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 90

4.2 Dementia 97

4.3 Mild Cognitive Impairment 108

4.4 Alzheimer's Disease 116

5 Companies Involved in Therapeutics Development 140

5.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 140

5.2 Dementia 148

5.3 Mild Cognitive Impairment 173

5.4 Alzheimer's Disease 182

6 Dormant Projects 286

6.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 286

6.2 Dementia 288

6.3 Mild Cognitive Impairment 292

6.4 Alzheimer's Disease 294

7 Discontinued Products 329

7.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 329

7.2 Dementia 330

7.3 Mild Cognitive Impairment 331

7.4 Alzheimer's Disease 332

8 Product Development Milestones 338

8.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 338

8.2 Dementia 339

8.3 Mild Cognitive Impairment 350

8.4 Alzheimer's Disease 357

9 Appendix 372

9.1 Methodology 372

9.2 Coverage 372

9.3 Secondary Research 372

9.4 Primary Research 372

9.5 Expert Panel Validation 372

9.6 Contact Us 372

9.7 Disclaimer 372

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) 14

Table 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS) 16

Table 3: Products under Development by Companies Cognitive Impairment Associated With Schizophrenia (CIAS) 17

Table 4: Number of Products under Development for Dementia 19

Table 5: Number of Products under Development by Companies, Dementia 21

Table 6: Number of Products under Development by Universities/Institutes, Dementia 23

Table 7: Products under Development by Companies, Dementia 24

Table 8: Products under Development by Universities/Institutes, Dementia 30

Table 9: Number of Products under Development for Mild Cognitive Impairment 31

Table 10: Number of Products under Development by Companies, Mild Cognitive Impairment 33

Table 11: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment 34

Table 12: Products under Development by Companies, Mild Cognitive Impairment 35

Table 13: Products under Development by Universities/Institutes, Mild Cognitive Impairment 37

Table 14: Number of Products under Development for Alzheimer’s Disease 38

Table 15: Number of Products under Development by Companies, Alzheimer’s Disease 40

Table 16: Number of Products under Development by Universities/Institutes, Alzheimer’s Disease 53

Table 17: Products under Development by Companies, Alzheimer’s Disease 57

Table 18: Products under Development by Universities/Institutes, Alzheimer’s Disease 82

Table 19: Number of Products by Stage and Target, Cognitive Impairment Associated With Schizophrenia (CIAS) 92

Table 20: Number of Products by Stage and Mechanism of Action, Cognitive Impairment Associated With Schizophrenia (CIAS) 94

Table 21: Number of Products by Stage and Route of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 96

Table 22: Number of Products by Stage and Molecule Type, Cognitive Impairment Associated With Schizophrenia (CIAS) 98

Table 23: Number of Products by Stage and Target, Dementia 100

Table 24: Number of Products by Stage and Mechanism of Action, Dementia 104

Table 25: Number of Products by Stage and Route of Administration, Dementia 107

Table 26: Number of Products by Stage and Molecule Type, Dementia 109

Table 27: Number of Products by Stage and Target, Mild Cognitive Impairment 111

Table 28: Number of Products by Stage and Mechanism of Action, Mild Cognitive Impairment 113

Table 29: Number of Products by Stage and Route of Administration, Mild Cognitive Impairment 115

Table 30: Number of Products by Stage and Molecule Type, Mild Cognitive Impairment 117

Table 31: Number of Products by Stage and Target, Alzheimer’s Disease 119

Table 32: Number of Products by Stage and Mechanism of Action, Alzheimer’s Disease 128

Table 33: Number of Products by Stage and Route of Administration, Alzheimer’s Disease 138

Table 34: Number of Products by Stage and Molecule Type, Alzheimer’s Disease 140

Table 35: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Astellas Pharma Inc 141

Table 36: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by AstraZeneca Plc 141

Table 37: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Bristol-Myers Squibb Co 142

Table 38: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Cadent Therapeutics 142

Table 39: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Coronis NeuroSciences Ltd 143

Table 40: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Eli Lilly and Co 143

Table 41: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by F. Hoffmann-La Roche Ltd 144

Table 42: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by H. Lundbeck AS 144

Table 43: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Heptares Therapeutics Ltd 145

Table 44: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Intra-Cellular Therapies Inc 145

Table 45: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Iproteos SL 146

Table 46: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Pfizer Inc 146

Table 47: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Sage Therapeutics Inc 147

Table 48: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Saniona AB 147

Table 49: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Spherium Biomed SL 148

Table 50: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Takeda Pharmaceutical Co Ltd 148

Table 51: Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Vanda Pharmaceuticals Inc 149

Table 52: Dementia – Pipeline by Acadia Pharmaceuticals Inc 149

Table 53: Dementia – Pipeline by Accera Inc 150

Table 54: Dementia – Pipeline by Acorda Therapeutics Inc 150

Table 55: Dementia – Pipeline by Actinogen Medical Ltd 151

Table 56: Dementia – Pipeline by Adamas Pharmaceuticals Inc 151

Table 57: Dementia – Pipeline by AgeneBio Inc 152

Table 58: Dementia – Pipeline by Alector LLC 152

Table 59: Dementia – Pipeline by Allergan Plc 153

Table 60: Dementia – Pipeline by Anavex Life Sciences Corp 153

Table 61: Dementia – Pipeline by Asceneuron SA 154

Table 62: Dementia – Pipeline by Axon Neuroscience SE 154

Table 63: Dementia – Pipeline by Axovant Sciences Ltd 155

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) 14

Figure 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS) 15

Figure 3: Number of Products under Development for Dementia 19

Figure 4: Number of Products under Development by Companies, Dementia 20

Figure 5: Number of Products under Development by Universities/Institutes, Dementia 23

Figure 6: Number of Products under Development for Mild Cognitive Impairment 31

Figure 7: Number of Products under Development by Companies, Mild Cognitive Impairment 32

Figure 8: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment 34

Figure 9: Number of Products under Development for Alzheimer’s Disease 37

Figure 10: Number of Products under Development by Companies, Alzheimer’s Disease 39

Figure 11: Number of Products under Development by Universities/Institutes, Alzheimer’s Disease 53

Figure 12: Number of Products by Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS) 91

Figure 13: Number of Products by Stage and Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS) 91

Figure 14: Number of Products by Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS) 93

Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS) 93

Figure 16: Number of Products by Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 95

Figure 17: Number of Products by Stage and Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 95

Figure 18: Number of Products by Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS) 97

Figure 19: Number of Products by Stage and Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS) 97

Figure 20: Number of Products by Top 10 Targets, Dementia 98

Figure 21: Number of Products by Stage and Top 10 Targets, Dementia 99

Figure 22: Number of Products by Top 10 Mechanism of Actions, Dementia 103

Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Dementia 103

Figure 24: Number of Products by Top 10 Routes of Administration, Dementia 106

Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Dementia 106

Figure 26: Number of Products by Top 10 Molecule Types, Dementia 108

Figure 27: Number of Products by Stage and Top 10 Molecule Types, Dementia 108

Figure 28: Number of Products by Top 10 Targets, Mild Cognitive Impairment 109

Figure 29: Number of Products by Stage and Top 10 Targets, Mild Cognitive Impairment 110

Figure 30: Number of Products by Top 10 Mechanism of Actions, Mild Cognitive Impairment 112

Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Mild Cognitive Impairment 112

Figure 32: Number of Products by Routes of Administration, Mild Cognitive Impairment 114

Figure 33: Number of Products by Stage and Routes of Administration, Mild Cognitive Impairment 114

Figure 34: Number of Products by Molecule Types, Mild Cognitive Impairment 116

Figure 35: Number of Products by Stage and Molecule Types, Mild Cognitive Impairment 116

Figure 36: Number of Products by Top 10 Targets, Alzheimer’s Disease 117

Figure 37: Number of Products by Stage and Top 10 Targets, Alzheimer’s Disease 118

Figure 38: Number of Products by Top 10 Mechanism of Actions, Alzheimer’s Disease 127

Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer’s Disease 127

Figure 40: Number of Products by Top 10 Routes of Administration, Alzheimer’s Disease 137

Figure 41: Number of Products by Stage and Top 10 Routes of Administration, Alzheimer’s Disease 137

Figure 42: Number of Products by Top 10 Molecule Types, Alzheimer’s Disease 139

Figure 43: Number of Products by Stage and Top 10 Molecule Types, Alzheimer’s Disease 139

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports